The hard part is that peptides do not survive being swallowed
Semaglutide is a 31-amino-acid peptide. Swallowed on its own it is broken down by stomach acid and digestive enzymes before it can be absorbed in any useful quantity. This is the reason GLP-1 drugs arrived as weekly injections in the first place, and it is not a marketing decision that a clever company can simply choose to route around.
The approved oral tablets solve it with an absorption enhancer called SNAC, which locally raises pH and promotes uptake across the stomach lining. That is a formulation achievement, and it is fragile enough that the label imposes real conditions on how the tablet is taken.
Keep that fragility in mind for the rest of this piece. When a product claims oral or sublingual delivery of the same molecule without the same formulation work, the question is not whether the claim is bold. It is whether anyone has published evidence that the drug arrives.
Three things sold as an oral GLP-1
First, Rybelsus: oral semaglutide, FDA-approved since 2019, indicated for type 2 diabetes rather than weight management. Real tablet, real approval, and the indication is not obesity.
Second, oral semaglutide 25 mg, which the FDA has approved for weight management — the first GLP-1 pill approved for that use. In the OASIS 4 trial it produced a mean weight reduction of about 13.6% at 64 weeks, against 2.2% on placebo. This is a genuine approved oral option and it did the work to get there.
Third, compounded sublingual or oral semaglutide — drops, troches, dissolving tablets — sold through telehealth. These are not FDA-approved products, they have not been through the trials above, and we are not aware of published bioavailability data establishing that any of them delivers a therapeutic dose by that route. That is the distinction that matters, and it is the one most likely to be blurred on a landing page.
How to tell which one you are being sold
The tells are reliable once you know them. Ask, in writing, and read the answer rather than the headline:
- Is this an FDA-approved product, and under which brand name and approval? A compounded preparation is not approved, and a straight answer here settles it.
- Is it a tablet taken on an empty stomach with plain water, or drops, a troche or something held under the tongue? Sublingual delivery of a peptide this size is the claim that needs evidence.
- What is the active ingredient, exactly? FDA has flagged compounded products using semaglutide salts — sodium or acetate forms — which are not the same active ingredient as the approved drug.
- Is there published bioavailability data for this specific preparation and route? “Our pharmacy stands behind it” is not that.
- What is the dose, in milligrams, and how is it measured at home? FDA has issued alerts about dosing errors with compounded GLP-1s, and the risk is highest wherever the patient measures the dose.
If you are prescribed an approved oral tablet, the instructions are not optional
The approved tablets are absorbed narrowly enough that the label specifies the conditions: taken on an empty stomach after waking, with no more than about four ounces of plain water, and at least 30 minutes before any food, other drink, or other oral medication.
That instruction reads like fussiness and is not. It is the difference between the formulation working as tested and the dose largely not being absorbed. If a daily routine with a strict fasted window is genuinely unworkable for you, that is a reasonable thing to raise with a prescriber before starting rather than after.
Follow the label and the prescriber over anything written here or on any provider's site, including on dosing, timing and interactions.
Why any of this is worth your attention
An oral option is legitimately attractive. Weekly injections are a real barrier for some people, and a pill that works removes it. That appetite is exactly why the category attracts products that borrow the credibility of the approved ones without doing the work.
We are not saying compounded sublingual semaglutide does nothing — we have not tested it, nobody has shown us data either way, and we are not going to assert a conclusion we cannot support. We are saying that the absence of published bioavailability evidence is the whole question for a route of administration this demanding, and that it is being marketed as though it were settled.
If a provider is selling you a version of a drug the FDA has not approved, by a route with no published evidence it works, the burden of proof sits with them. Ask for it in writing. What comes back will tell you a great deal.